Immunology and Biotherapies
21.5K views | +11 today
Follow
 
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert C FAURE's insight:

We choose Scoop.it as preferred curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Can this cooler save kids from dying? | Bill Gates

Can this cooler save kids from dying? | Bill Gates | Immunology and Biotherapies | Scoop.it
Bill Gates shares two remarkable innovations that are helping deliver vaccines to the most remote places on earth.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

WELBIO - CEMIP, a new player in the acquired resistance to targeted therapies

WELBIO - CEMIP, a new player in the acquired resistance to targeted therapies | Immunology and Biotherapies | Scoop.it
WELBIO, Institut wallon virtuel de recherche d'excellence dans les domaines des sciences de la vie - Walloon Excellence in Lifesciences & BIOtechnology. Alain Chariot's team , WELBIO investigator at the University of Liège, shows that the CEMIP protein plays a role in resistance to...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge

A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge | Immunology and Biotherapies | Scoop.it
The HIV Env trimer exhibits a closed confirmation and restricts access to known antibody binding sites. Here the authors show that a small-molecule CD4-mimetic compound binds the HIV Env trimer and enhances antibody-mediated protection in a non-human primate model of infection.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association | Immunology and Biotherapies | Scoop.it

 bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rdCongress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina,Charleston, South Carolina.

 

All patients (n=4) in Group C with ≥ 3 months follow-up consistently producing ≥ 30% anti-sickling HbAT87Q –

– First Group C patient generating a normal total hemoglobin of 14.2 g/dL with over 60% anti-sickling HbAT87Q at 6 months –

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

KLRD1-expressing natural killer cells predict influenza susceptibility | Genome Medicine | Full Text

KLRD1-expressing natural killer cells predict influenza susceptibility | Genome Medicine | Full Text | Immunology and Biotherapies | Scoop.it
Influenza infects tens of millions of people every year in the USA. Other than notable risk groups, such as children and the elderly, it is difficult to predict what subpopulations are at higher risk of infection.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III

Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III | Immunology and Biotherapies | Scoop.it
One mAb, m301, broadly neutralized the currently circulating ZIKV strains and showed a synergistic effect with another mAb, m302, in neutralizing ZIKV in vitro and in a mouse model of ZIKV infection. Interestingly, epitope mapping and competitive binding studies suggest that m301 and m302 bind adjacent regions of the DIII C–C′ loop, which represents a recently identified cryptic epitope that is intermittently exposed in an uncharacterized virus conformation. This study extended our understanding of antigenic epitopes of ZIKV antibodies and has direct implications for the design of ZIKV vaccines.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Characterization of glycoengineered anti-HER2 monoclonal antibodies produced by using a silkworm–baculovirus expression system | The Journal of Biochemistry | Oxford Academic

Characterization of glycoengineered anti-HER2 monoclonal antibodies produced by using a silkworm–baculovirus expression system | The Journal of Biochemistry | Oxford Academic | Immunology and Biotherapies | Scoop.it
Abstract. Silkworm–baculovirus expression systems are efficient means for the production of recombinant proteins that provide high expression levels and post-t

Via Krishan Maggon
Gilbert C FAURE's insight:

silkworm?

more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

MSCs in research: current trends and future developments

MSCs in research: current trends and future developments | Immunology and Biotherapies | Scoop.it
In this infographic, we present the results of our latest spotlight survey on MSCs.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Immunotherapy Biomarker Predicts Lung Cancer Response and Survival

Immunotherapy Biomarker Predicts Lung Cancer Response and Survival | Immunology and Biotherapies | Scoop.it
Researchers have now discovered a method for predicting the likelihood of treatment success for immunotherapy
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1β Inflammatory Response in Active Ulcerative Colitis

REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1β Inflammatory Response in Active Ulcerative Colitis | Immunology and Biotherapies | Scoop.it
Infiltration of neutrophils into colonic mucosa has been associated with the severity of ulcerative colitis (UC). We investigated the effect of disease microenvironment on the release of neutrophil extracellular traps (NETs) as well as the involved mechanisms in NETosis and whether certain NET...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy | NEJM

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy | NEJM | Immunology and Biotherapies | Scoop.it

Abstract
BACKGROUND
In efficacy trials of a tetravalent dengue vaccine (CYD-TDV), excess hospitalizations for dengue were observed among vaccine recipients 2 to 5 years of age. Precise risk estimates according to observed dengue serostatus could not be ascertained because of the limited numbers of samples collected at baseline. We developed a dengue anti–nonstructural protein 1 (NS1) IgG enzyme-linked immunosorbent assay and used samples from month 13 to infer serostatus for a post hoc analysis of safety and efficacy.

METHODS
In a case–cohort study, we reanalyzed data from three efficacy trials. For the principal analyses, we used baseline serostatus determined on the basis of measured (when baseline values were available) or imputed (when baseline values were missing) titers from a 50% plaque-reduction neutralization test (PRNT50), with imputation conducted with the use of covariates that included the month 13 anti-NS1 assay results. The risk of hospitalization for virologically confirmed dengue (VCD), of severe VCD, and of symptomatic VCD according to dengue serostatus was estimated by weighted Cox regression and targeted minimum loss–based estimation.

RESULTS
Among dengue-seronegative participants 2 to 16 years of age, the cumulative 5-year incidence of hospitalization for VCD was 3.06% among vaccine recipients and 1.87% among controls, with a hazard ratio (vaccine vs. control) through data cutoff of 1.75 (95% confidence interval [CI], 1.14 to 2.70). Among dengue-seronegative participants 9 to 16 years of age, the cumulative incidence of hospitalization for VCD was 1.57% among vaccine recipients and 1.09% among controls, with a hazard ratio of 1.41 (95% CI, 0.74 to 2.68). Similar trends toward a higher risk among seronegative vaccine recipients than among seronegative controls were also found for severe VCD. Among dengue-seropositive participants 2 to 16 years of age and those 9 to 16 years of age, the cumulative incidence of hospitalization for VCD was 0.75% and 0.38%, respectively, among vaccine recipients and 2.47% and 1.88% among controls, with hazard ratios of 0.32 (95% CI, 0.23 to 0.45) and 0.21 (95% CI, 0.14 to 0.31). The risk of severe VCD was also lower among seropositive vaccine recipients than among seropositive controls.

CONCLUSIONS
CYD-TDV protected against severe VCD and hospitalization for VCD for 5 years in persons who had exposure to dengue before vaccination, and there was evidence of a higher risk of these outcomes in vaccinated persons who had not been exposed to dengue. (Funded by Sanofi Pasteur; ClinicalTrials.gov numbers, NCT00842530, NCT01983553, NCT01373281, and NCT01374516.)

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Personal cancer vaccines show positive results

Personal cancer vaccines show positive results | Immunology and Biotherapies | Scoop.it
Immunotherapies are moving to the forefront of cancer treatment. Recent clinical trials have demonstrated that these approaches can be personalized to the unique mutations profile of each individual's tumor, igniting new ...
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) | Immunology and Biotherapies | Scoop.it
Abstract
CD19-specific chimeric antigen receptor (CAR) T cell therapy is highly effective against relapsed or refractory acute lymphoblastic leukemia (ALL), but is hindered by neurotoxicity. In 53 adult patients with ALL, we found a significant association of severe neurotoxicity with high pretreatment disease burden, higher peak CAR T cell expansion and early and higher elevations of proinflammatory cytokines in blood. Patients with severe neurotoxicity had evidence of blood-cerebrospinal fluid (CSF) barrier disruption correlating with neurotoxicity grade without association with CSF white blood cell count or CAR T-cell quantity in CSF. Proinflammatory cytokines were enriched in CSF during severe neurotoxicity with disproportionately high levels of IL6, IL8, MCP1 and IP10, suggesting central nervous system (CNS)-specific production. Seizures, seizure-like activity, myoclonus and neuroimaging characteristics suggested excitatory neurotoxicity, and we found elevated levels of endogenous excitatory agonists in CSF during neurotoxicity.

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System

Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System | Immunology and Biotherapies | Scoop.it
Enhancing T cell responses against both viral and tumor Ags requires efficient costimulation and directed delivery of peptide Ags into APCs. Long peptide vaccines are considered favorable vaccine moieties from a clinical perspective, as they can harbor more than one immunogenic epitope enabling treatment of a broader target population. In addition, longer peptides are not extracellularly loaded on MHC class I; rather, they require intracellular processing and will thereby be presented to T cells mainly by professional APCs, thereby avoiding the risk of tolerance induction. The drawback of peptide vaccines regardless of peptide length is that naked peptides are not actively targeted to and taken up by APCs, and the standard nonconjugated adjuvant-peptide mixtures do not ensure cotargeting of the two to the same APC. We have identified a tetanus toxin–derived B cell epitope that can mediate the formation of immune complexes in the presence of circulating Abs. In this study, we show that these immune complexes improve both Ag uptake by APCs (blood monocytes and CD1c+ dendritic cells) and consequently improve CD8+ T cell recall responses in a human ex vivo blood loop system. The uptake of the peptide conjugate by blood monocytes is dependent on Abs and the complement component C1q. We envision that this strategy can be used to facilitate active uptake of Ags into APCs to improve T cell responses against pathogens or cancer.

This article is featured in In This Issue , p.[3][1]

[1]: /lookup/volpage/201/3
more...
No comment yet.
Rescooped by Gilbert C FAURE from Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
Scoop.it!

DSG2 Is a Functional Cell Surface Marker for Identification and Isolation of Human Pluripotent Stem Cells

DSG2 Is a Functional Cell Surface Marker for Identification and Isolation of Human Pluripotent Stem Cells | Immunology and Biotherapies | Scoop.it
DSG2 is a desmosomal cadherin molecule. In this article, Min and colleagues show that DSG2 is a valuable PSC surface marker that is essential for the maintenance of PSC self-renewal and pluripotency and the acquisition of pluripotency during somatic cell reprogramming through the regulation of...

Via Krishan Maggon
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phas...

Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phas... | Immunology and Biotherapies | Scoop.it
REGN3470-3471-3479 was well tolerated, displayed linear pharmacokinetics, and did
not lead to detectable immunogenicity. These data support further clinical development
of REGN3470-3471-3479 as a single-dose therapeutic drug for acute Ebola virus infection.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05‐09 antigen could be a malaria vaccine candidate

Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05‐09 antigen could be a malaria vaccine candidate | Immunology and Biotherapies | Scoop.it
Although it is generally agreed that an effective vaccine would greatly accelerate the control of malaria, the lone registered malaria vaccine Mosquirix™ has an efficacy of 30%‐60% that wanes rapidly, indicating a need for improved second‐generation ...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Epidermal Growth Factor Receptor Immunohistochemistry

Epidermal Growth Factor Receptor Immunohistochemistry | Immunology and Biotherapies | Scoop.it
The ISEL (Iressa Survival Evaluation in Lung Cancer) clinical trial evaluated the efficacy of gefitinib versus placebo in pretreated nonsmall-cell lung cancer patients. Two different antibodies, scoring systems, and cutoff points of epidermal growth factor ...
more...
No comment yet.
Rescooped by Gilbert C FAURE from Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
Scoop.it!

Mass Producing Stem Cells in Suspension | Orthopedics This Week

Mass Producing Stem Cells in Suspension | Orthopedics This Week | Immunology and Biotherapies | Scoop.it
Mass Producing Stem Cells in Suspension...

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

The promise and challenges of immune agonist antibody development in cancer

The promise and challenges of immune agonist antibody development in cancer | Immunology and Biotherapies | Scoop.it
Co-stimulatory receptors mediate the anticancer immune response. This Review discusses the current efforts in targeting co-stimulatory receptors with agonist antibodies and the landscape of agonist antibodies in clinical development for cancer treatment.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Safety and efficacy of epicutaneous immunotherapy for food allergy - Wang - 2018 - Pediatric Allergy and Immunology - Wiley Online Library

Safety and efficacy of epicutaneous immunotherapy for food allergy - Wang - 2018 - Pediatric Allergy and Immunology - Wiley Online Library | Immunology and Biotherapies | Scoop.it
Food allergy is increasingly common in children, affecting about 4%‐8%. The mainstays of management remain allergen avoidance and emergency preparedness to treat allergic reactions with emergency medications. Unfortunately, these approaches are unsatisfactory for many patients and their families as the restrictions, constant vigilance, and unpredictable severity of allergic reactions negatively impact quality of life. In recent decades, there has been significant interest in developing treatments for food allergy that lead to desensitization to increase thresholds for triggering allergic reactions and decrease the risk of reacting to allergen‐contaminated food products. Epicutaneous immunotherapy (EPIT) is a novel therapy that is currently under investigation, delivering allergen via repeated applications to the skin and targeting antigen‐presenting cells in the superficial skin layers. Murine models have demonstrated that allergen uptake is an active process by skin dendritic cells with subsequent migration to draining lymph nodes. Allergen exposure to the non‐vascularized epidermis limits systemic absorption, contributing to the high‐safety profile. Results from murine experiments showed that EPIT has comparable efficacy as subcutaneous immunotherapy in terms of challenge outcomes, airway hyper‐responsiveness, and immunologic parameters. Several clinical trials of EPIT have recently been completed or are ongoing. Results support the high safety and tolerability of this approach. Efficacy data suggest that the change in threshold eliciting dose following 1 year of therapy is less than that seen compared to high‐dose (2‐4 g peanut protein) oral immunotherapy, but more prolonged treatment with EPIT appears to lead to increasing desensitization. Additional data from larger‐scale studies should provide a more robust assessment of safety and efficacy of EPIT.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

New windows open for immunotherapy in lung cancer

New windows open for immunotherapy in lung cancer | Immunology and Biotherapies | Scoop.it
Activating immune cells to destroy tumours is an effective strategy for treating an advanced lung cancer — but only for some people. Evidence that this approach has potential in early disease and as a combination therapy has now emerged.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Humoral and cellular immune responses to Yersinia pestis Pla antigen in humans immunized with live plague vaccine

Humoral and cellular immune responses to Yersinia pestis Pla antigen in humans immunized with live plague vaccine | Immunology and Biotherapies | Scoop.it
Author summary Yersinia pestis, the causative agent of plague, has been recognized as one of the most devastating pathogen experienced by mankind. It remains endemic in many parts of the world, and is considered emerging pathogen.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Chimeric Antigen Receptor T Cell (CAR T) Therapy

Chimeric Antigen Receptor T Cell (CAR T) Therapy | Immunology and Biotherapies | Scoop.it
Individualized CAR T therapy uses a patient’s own immune system to fight certain types of cancers. A patient’s T cells are extracted and reprogrammed outside of the body to recognize and fight cancer cells and other cells expressing a particular antigen.

Via Krishan Maggon
more...
No comment yet.